Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 597 일 전

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | 705 일 전

CRISPR Therapeutics Says FDA Grants RMAT Designation To CTX130

Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

RTTNews | 1148 일 전

Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.

RTTNews | 1227 일 전

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 1233 일 전

Iceland Unexpectedly Cuts Policy Rate By 25 Bps

Iceland's central bank lowered its key interest rate unexpectedly as the economy is expected to recover more slowly than previously anticipated due to worsening prospects for exports. The Monetary Policy Committee of the Central Bank of Iceland, led by Governor Ásgeir Jónsson, unanimously decided to cut the rate on seven-day term deposits to 7.25 percent from 7.50 percent.

RTTNews | 1 시간 39 분 전

UK Stocks Turning In Mixed Performance; Mining Stocks Move Up

U.K. stocks are turning in a mixed performance Wednesday morning with investors reacting to earnings updates and other corporate news, in addition to digesting the data showing a slower than expected increase in the nation's consumer price inflation in the month of October.

RTTNews | 2 시간 57 분 전

Yen Falls Against Majors

The Japanese yen weakened against other major currencies in the European session on Wednesday.

RTTNews | 2 시간 57 분 전

EURUSD	1.15903	GBPUSD	1.31274	AUDUSD	0.64891
USDJPY	156.084	USDCAD	1.40058	USDCHF	0.80102